Publicaciones en colaboración con investigadores/as de University Medical Center Utrecht (33)

2024

  1. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

2023

  1. Quantification of time delay between screening and subsequent initiation of contact isolation for carriers of extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales: A post hoc subgroup analysis of the R-GNOSIS WP5 Trial

    Infection Control and Hospital Epidemiology, Vol. 4

  2. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2022

  1. Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy

    Open Forum Infectious Diseases, Vol. 9, Núm. 4

  2. Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections

    BMC Microbiology, Vol. 22, Núm. 1

  3. Taxonomic position, antibiotic resistance and virulence factors of clinical Achromobacter isolates

    Frontiers in bioscience (Scholar edition), Vol. 14, Núm. 2, pp. 9

  4. Whole-genome analysis of Haemophilus influenzae strains isolated from persons with cystic fibrosis

    Journal of medical microbiology, Vol. 71, Núm. 8

2021

  1. Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2578-2585

  2. Characterization of clinical Ralstonia strains and their taxonomic position

    Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology, Vol. 114, Núm. 10, pp. 1721-1733

  3. Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 4, pp. 984-992

2020

  1. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial

    The Lancet Infectious Diseases, Vol. 20, Núm. 5, pp. 575-584

  2. Draft genome sequence of the strain 16-537536, isolated from a patient with bronchiectasis and its relationship to the Pseudomonas koreensis group of the Pseudomonas fluorescens complex

    BMC Research Notes, Vol. 13, Núm. 1

  3. Susceptibility of pseudomonas aeruginosa recovered from cystic fibrosis patients to murepavadin and 13 comparator antibiotics

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 2

2019

  1. Antimicrobial susceptibility of non-fermenting Gram-negative pathogens isolated from cystic fibrosis patients

    International Journal of Antimicrobial Agents, Vol. 53, Núm. 1, pp. 84-88

  2. Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: A prevalence survey in a Spanish University Hospital

    BMJ Open, Vol. 9, Núm. 3

  3. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

    Clinical Infectious Diseases, Vol. 69, Núm. 10, pp. 1812-1816

  4. Whole-genome analysis of Pandoraea species strains from cystic fibrosis patients

    Future microbiology, Vol. 14, pp. 1357-1367

2018

  1. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance

    Intensive Care Medicine

  2. Characterization of carbapenemase-producing Enterobacteriaceae from colonized patients in a university hospital in Madrid, Spain, during the R-GNOSIS project depicts increased clonal diversity over time with maintenance of high-risk clones

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 3039-3043

  3. Defining antimicrobial resistance in cystic fibrosis

    Journal of Cystic Fibrosis, Vol. 17, Núm. 6, pp. 696-704